Devin M Parker1, Allen D Everett2, Meagan E Stabler3, Marshall L Jacobs4, Jeffrey P Jacobs5, Luca Vricella4, Heather Thiessen-Philbrook6, Chirag R Parikh6, Cedric Manlhiot2, Jeremiah R Brown7. 1. The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, New Hampshire; Department of Epidemiology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire. Electronic address: devin.m.parker.gr@dartmouth.edu. 2. Division of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire. 4. Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Division of Cardiac Surgery, University of Florida, Gainesville, Florida. 6. Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland. 7. The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine, Lebanon, New Hampshire; Department of Epidemiology, Dartmouth Geisel School of Medicine, Hanover, New Hampshire; Department of Biomedical Data Science, Geisel School of Medicine, Lebanon, New Hampshire.
Abstract
BACKGROUND: Approximately 10% to 20% of children are readmitted after congenital heart surgery. Very little is known about biomarkers as predictors of risk of unplanned readmission after pediatric congenital heart surgery. Novel cardiac biomarker ST2 may be associated with risk of unplanned readmission. ST2 concentrations are believed to reflect cardiovascular stress and fibrosis. Our objective was to explore the relationship between pre- and postoperative ST2 biomarker levels and risk of readmission within 1 year after congenital heart surgery. METHODS: We prospectively enrolled pediatric patients aged < 18 years who underwent at least 1 congenital heart operation at Johns Hopkins Hospital from 2010 to 2014. Plasma samples were collected immediately before surgery and at the end of bypass. We used Kaplan-Meier survival analysis and multivariable Cox regression models to adjust for variables used in The Society of Thoracic Surgeons Congenital Heart Surgery Database mortality risk model. RESULTS: Of our cohort of 145 patients, we found 39 children with readmissions within 365 days. The median time to unplanned readmission was 54 days (interquartile range, 10-153). Kaplan-Meier analysis demonstrated a significant difference across terciles of pre- and postoperative ST2 biomarker levels. After adjustment, elevated serum levels of ST2 measured preoperatively and postoperatively were associated with increased risk of readmission (hazard ratio, 2.5-3.7; all P < .05). CONCLUSIONS: Elevated levels of ST2 are significantly associated with increased risk of unplanned readmission within 1 year after pediatric congenital heart surgery. Novel serum biomarker ST2 can be used for risk stratification or estimating postsurgical prognosis.
BACKGROUND: Approximately 10% to 20% of children are readmitted after congenital heart surgery. Very little is known about biomarkers as predictors of risk of unplanned readmission after pediatric congenital heart surgery. Novel cardiac biomarker ST2 may be associated with risk of unplanned readmission. ST2 concentrations are believed to reflect cardiovascular stress and fibrosis. Our objective was to explore the relationship between pre- and postoperative ST2 biomarker levels and risk of readmission within 1 year after congenital heart surgery. METHODS: We prospectively enrolled pediatric patients aged < 18 years who underwent at least 1 congenital heart operation at Johns Hopkins Hospital from 2010 to 2014. Plasma samples were collected immediately before surgery and at the end of bypass. We used Kaplan-Meier survival analysis and multivariable Cox regression models to adjust for variables used in The Society of Thoracic Surgeons Congenital Heart Surgery Database mortality risk model. RESULTS: Of our cohort of 145 patients, we found 39 children with readmissions within 365 days. The median time to unplanned readmission was 54 days (interquartile range, 10-153). Kaplan-Meier analysis demonstrated a significant difference across terciles of pre- and postoperative ST2 biomarker levels. After adjustment, elevated serum levels of ST2 measured preoperatively and postoperatively were associated with increased risk of readmission (hazard ratio, 2.5-3.7; all P < .05). CONCLUSIONS: Elevated levels of ST2 are significantly associated with increased risk of unplanned readmission within 1 year after pediatric congenital heart surgery. Novel serum biomarker ST2 can be used for risk stratification or estimating postsurgical prognosis.
Authors: Jeffrey W Meeusen; Jonathan N Johnson; Amber Gray; Patricia Wendt; John L Jefferies; Allan S Jaffe; Leslie J Donato; Amy K Saenger Journal: Clin Biochem Date: 2015-08-12 Impact factor: 3.281
Authors: Devin M Parker; Allen D Everett; Meagan E Stabler; Luca Vricella; Marshall L Jacobs; Jeffrey P Jacobs; Heather Thiessen-Philbrook; Chirag R Parikh; Jeremiah R Brown Journal: J Card Surg Date: 2019-04-03 Impact factor: 1.620
Authors: Ravi V Shah; Annabel A Chen-Tournoux; Michael H Picard; Roland R J van Kimmenade; James L Januzzi Journal: Eur J Heart Fail Date: 2010-06-05 Impact factor: 15.534
Authors: Marshall L Jacobs; Jeffrey P Jacobs; Kevin D Hill; Sean M O'Brien; Sara K Pasquali; David Vener; S Ram Kumar; Karen Chiswell; Robert H Habib; David M Shahian; Felix G Fernandez Journal: Ann Thorac Surg Date: 2018-07-25 Impact factor: 4.330
Authors: Marshall L Jacobs; Sean M O'Brien; Jeffrey P Jacobs; Constantine Mavroudis; Francois Lacour-Gayet; Sara K Pasquali; Karl Welke; Christian Pizarro; Felix Tsai; David R Clarke Journal: J Thorac Cardiovasc Surg Date: 2012-07-24 Impact factor: 5.209
Authors: James L Januzzi; W Frank Peacock; Alan S Maisel; Claudia U Chae; Robert L Jesse; Aaron L Baggish; Michelle O'Donoghue; Rahul Sakhuja; Annabel A Chen; Roland R J van Kimmenade; Kent B Lewandrowski; Donald M Lloyd-Jones; Alan H B Wu Journal: J Am Coll Cardiol Date: 2007-07-30 Impact factor: 24.094
Authors: Nisha Bansal; Ronit Katz; Stephen Seliger; Christopher DeFilippi; Mark J Sarnak; Joseph A Delaney; Robert Christenson; Ian H de Boer; Bryan Kestenbaum; Cassianne Robinson-Cohen; Joachim H Ix; Michael G Shlipak Journal: Am J Kidney Dis Date: 2016-01-29 Impact factor: 8.860
Authors: Shoji Sanada; Daihiko Hakuno; Luke J Higgins; Eric R Schreiter; Andrew N J McKenzie; Richard T Lee Journal: J Clin Invest Date: 2007-05-10 Impact factor: 14.808
Authors: Michael D Green; Devin M Parker; Allen D Everett; Luca Vricella; Marshall L Jacobs; Jeffrey P Jacobs; Jeremiah R Brown Journal: Ann Thorac Surg Date: 2020-08-25 Impact factor: 5.102